Challenges and solutions faced by using compressed air in pharmaceutical production

Analysis of core challenges

In drug production, compressed air directly contacts raw materials, packaging materials and production equipment, and its cleanliness directly affects drug quality and patient safety. Here are the five core challenges facing the industry:

1. risk of microbial contamination
   • International standards require:
     • ISO 8573-7 Class 0: Microbial content in compressed air ≤ 0.1 CFU/m³ (airborne bacteria)
     • EU GMP Annex 1: Gas for sterile preparations must pass through a 0.22μm sterilization filter
   • Risk scenarios:
     • When the compressed air dew point is greater than-40℃ (violates ISO 8573-3 Class 2), microorganisms are bred in the condensate water in the pipeline
     • Excessive bioburden leads to a higher aseptic filling failure rate of 30%(Data source: PDA TR52 report)
2. Oil and particulate pollution
   • Strict standards:
     • ISO 8573-1 Class 0: Oil content ≤ 0.01mg/m³, particulate matter ≤ 0.1μm (20 pieces/m³)
     • FDA 21 CFR 211.65: Prohibition of compressed air contamination of surfaces in direct contact with drugs
   • Consequences of pollution:
     • The oil mist is adsorbed on the lyophilizer plate, resulting in a detection rate of foreign matter in lyophilized products of ↑ 12%(Case: 2023 FDA warning letter)
     • 0.5μm particles block the sterilization filter, shortening the filter life to 60% of normal value
3. Dew point and humidity control
   • Process requirements:
     • The lyophilization process requires dew point ≤ -70℃ (complies with ISO 8573-3 Class 1)
     • The coating process needs to maintain RH of 30%-40%(to prevent cracking of the coating)
   • Out-of-control effects:
     • Dew point> -40℃ causes the moisture absorption rate of aluminum-plastic blister packaging to ↑ 8%, causing drug deliquescence
     • Fluctuations in humidity cause powder to adhere to the die of the tablet press, and the difference in tablet weight exceeds the standard (violation of USP <1217>standards)
4. System verification and monitoring
   • Compliance requirements:
     • ASTM F838: Need to verify that the filter retention efficiency for Brevundimonas diminuta is ≥ 10 CFU
     • GAMP5: The compressed air system requires DQ/IQ/OQ/PQ full life cycle verification
   • Implementation difficulties:
     • Online particle counters need to meet 0.1μm resolution (ISO 21501-4 calibration specification)
     • Microbial sampling is easily affected by airflow impact (sampling error ≥ 50%, static sampling method must be followed by ISO 8573-8)
5. risk of cross-contamination
   • Key control points:
     • When multiple products are produced in line, a dedicated circuit is required for compressed air (complies with EMA Guidelines on setting health-based exposure limits)
     • Active ingredient residue detection limit ≤ 0.001%(verified by HPLC-MS)
   • Accident cases:
     • A pharmaceutical factory lost $23 million in recall due to cross-contamination of β-lactam drugs due to shared air pressure systems (2022 MHRA Notice)

Technical solutions and standards comparison

Economic impact analysis

summary

The compressed air system in pharmaceutical production needs to meet the three core requirements of zero pollution, ultra-low dew point, and full life cycle verification. Shanghai Granklin’s modular oil-free air compression system has passed ISO 8573-1 Class 0 certification. It combines online particle monitoring and automatic sterilization design to provide high-risk processes such as freeze-drying and aseptic filling. Clean air solutions that comply with the PDA TR52 guidelines control the risk of microbial contamination to a level of 10 ° C.